The country's largest software services exporter Tata Consultancy Services has launched a new platform to enable data-driven site selection and activation processes for clinical trials, the company said in a media statement.
Called Site Feasibility, the new platform is part of TCS' advanced drug development (ADD) suite and digitises the clinical trial site selection process for better outcomes for the company's life sciences customers.
The platform is a single, integrated product for analysing sites, patient population, investigator profiles, treatment facilities and other parameters while planning for multi-site clinical trials by drug companies, the statement said.
These processes are currently done manually and digitising will have a huge impact on the study outcomes by avoiding sub-optimal site choices that can result in significant delays and costs, according to the Mumbai-based IT services firm.
“We are leveraging our deep knowledge of the life sciences industry to expand the capabilities of the TCS ADD suite of cloud platforms. The platform will help our customers digitally transform the most critical study design aspects of their clinical trials and drive superior outcomes,” said Debashis Ghosh, president, life sciences and healthcare, TCS.
The platform consolidates data residing on multiple systems within the enterprise into a central repository, TCS said. Once the data is centralised, insights can be derived to identify the sites best suited for a given study protocol, with the most appropriate patient population and investigators, the statement added.
TCS said that digitisation and automation of the entire assessment and selection process will enable the efficient and coordinated management of hundreds of concurrent clinical trial feasibility studies.
The platform is also fully integrated with the TCS connected clinical trials e-Survey platform, providing customers with an end-to-end solution for conducting site surveys and analysing the survey responses, it added.